middle.news
Clarity Advances Cu-SAR-bisPSMA with $106M Cash and Triple FDA Fast Track Designations
4:15am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Clarity Advances Cu-SAR-bisPSMA with $106M Cash and Triple FDA Fast Track Designations
4:15am on Monday 2nd of June, 2025 AEST
Key Points
Strong cash position of $95.1 million plus $11.1 million R&D tax incentive
Prioritisation of Cu-SAR-bisPSMA for prostate cancer diagnostics and therapeutics
Three FDA Fast Track Designations granted for SAR-bisPSMA products
Advancement of SECuRE Phase II trial with promising safety and efficacy data
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CU6
OPEN ARTICLE